Skip to main content
Log in

Methylphenidate still first line, but combination treatment often required in adults with attention deficit hyperactivity disorder

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Wilens TE, Biederman J, Spencer TJ. Pharmacotherapy of attention deficit hyperactivity disorder in adults. CNS Drugs 1998 May; 9(5): 347–56

    Article  CAS  Google Scholar 

  2. Fargason RE, Ford CV. Attention deficit hyperactivity disorder in adults: diagnosis, treatment and prognosis. South Med J 1994 Mar; 87(3): 302–9

    Article  PubMed  CAS  Google Scholar 

  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  4. British National Formulary. No. 36. London: The Pharmaceutical Press, 1998 Sep

  5. Wender PH, Reimherr FW. Bupropion treatment of attention deficit hyperactivity disorder in adults. Am J Psychiatry 1990; 147: 1018–20

    PubMed  CAS  Google Scholar 

  6. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992; 15(1): 191–222

    PubMed  CAS  Google Scholar 

  7. Langer DH, Sweeney KP, Bartenbach DE, et al. Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend 1986; 17: 213–27

    Article  PubMed  CAS  Google Scholar 

  8. Wilens TE, Biederman J, Mick E, et al. A systematic assessment of tricyclic antidepressants in the treatment of adult attention deficit hyperactivity disorder. J Nerv Ment Dis 1995; 184: 48–50

    Article  Google Scholar 

  9. Wilens TE, Biederman J, Prince J, et al. A double-blind, placebo-controlled trial of desipramine for adults with ADHD. Am J Psychiatry 1996; 153: 1147–53

    PubMed  CAS  Google Scholar 

  10. Wender PH, Wood DR, Reimherr FW, et al. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res 1983; 9: 329–36

    Article  PubMed  CAS  Google Scholar 

  11. Wender PH, Wood DR, Reimherr FW. Pharmacological treatment of attention deficit disorder residual type (ADD.RT, ‘minimal brain dysfunction’, ‘hyperactivity’) in adults. Psychopharmacol Bull 1985; 21: 222–30

    PubMed  CAS  Google Scholar 

  12. Ernst M, Liebenauer L, Jons P, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull 1996; 32: 327–34

    PubMed  CAS  Google Scholar 

  13. Mattes JA. Propranolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 1986; 6: 299–302

    Article  PubMed  CAS  Google Scholar 

  14. Conners C, Levin ED, Sparrow E, et al. Nicotine and attention in adult attention deficit hyperactivity disorder. Psychopharmacol Bull 1996; 32: 67–73

    PubMed  CAS  Google Scholar 

  15. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1993;3: 1–10

    Article  PubMed  CAS  Google Scholar 

  16. Ratey J, Greenberg M, Lindem K. Combination of treatments for attention deficit disorders in adults. J Nerv Ment Dis 1991; 176: 699–701

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Methylphenidate still first line, but combination treatment often required in adults with attention deficit hyperactivity disorder. Drugs Ther. Perspect 13, 8–12 (1999). https://doi.org/10.2165/00042310-199913030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199913030-00004

Navigation